Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pharmacogenomic Testing Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

NCT03023891
View directory record Official record
Conditions
Glucocorticoids Toxicity, Glucose Intolerance
Interventions
Prednisone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 3, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813
View directory record Official record
Conditions
Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
781
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Pharmacogenomic Testing in Primary Care

NCT03270891
View directory record Official record
Conditions
Antidepressants Causing Adverse Effects in Therapeutic Use
Interventions
PGx test
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

NCT00025363
View directory record Official record
Conditions
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 3, 2026, 5:34 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomic Informed Statin Prescribing

NCT06568601
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Pharmacogenetic and polygenic risk testing, Active control
Genetic · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Not listed No phase listed Observational

Pharmacogenomics of Heparin-Induced Thrombocytopenia

NCT02717039
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Blood Draw
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 3, 2026, 5:34 AM EDT
Recruiting Phase 4 Interventional

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

NCT07177300
View directory record Official record
Conditions
Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)
Interventions
PK-optimized oral hydroxyurea at MTD until 15 years of age.
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 3, 2026, 5:34 AM EDT
Completed No phase listed Observational

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

NCT00830570
View directory record Official record
Conditions
Embolism and Thrombosis, Embolism, Vascular Diseases, Warfarin, Venous Thromboembolism, Thrombosis, Thromboembolism
Interventions
CYP 2C9 and VKORC1 Testing for Warfarin
Other
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Sep 3, 2026, 5:34 AM EDT
Recruiting Phase 4 Interventional

Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score

NCT07490067
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00088894
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, bevacizumab, placebo, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy

NCT06748040
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Timing of return of results
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
1,874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 3, 2026, 5:34 AM EDT
Completed No phase listed Observational

Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease

NCT03005080
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

NCT03370718
View directory record Official record
Conditions
Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
Interventions
Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 3, 2026, 5:34 AM EDT
Enrolling by invitation Not applicable Interventional

An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

NCT06660264
View directory record Official record
Conditions
Pharmacogenetics, Pharmacogenomic Drug Interaction
Interventions
Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 3, 2026, 5:34 AM EDT
Withdrawn Not applicable Interventional

Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support

NCT03952494
View directory record Official record
Conditions
Depression
Interventions
Genomind®Professional PGx Express TM
Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 3, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02443077
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 5:34 AM EDT
Completed No phase listed Observational

Genetic Evaluation for Medication Selection (GEMS) Study

NCT03736057
View directory record Official record
Conditions
Dementia, Psychiatric Disorders Mood, Behavior Disorders
Interventions
Delayed results of pharmacogenomic results
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
40 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 3, 2026, 5:34 AM EDT
Withdrawn Not applicable Interventional

Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans

NCT04893395
View directory record Official record
Conditions
Pharmacogenetics, Depressive Disorder, Major, Medication Therapy Management
Interventions
Pharmacogenomic Screening
Other
Lead sponsor
Auburn University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 3, 2026, 5:34 AM EDT
Completed No phase listed Observational

Pharmacogenomics and Effective Treatment With Clopidogrel

NCT01611545
View directory record Official record
Conditions
Pharmacogenomics and Cardiovascular Events
Interventions
Pharmacogenomics
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

NCT02634177
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Assay-guided treatment (AGT), Treatment-as-usual (TAU)
Genetic · Other
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 3, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Genomic Opioid Optimization of Dosing and Selections (GOODS) Study

NCT03579121
View directory record Official record
Conditions
Perioperative/Postoperative Complications
Interventions
Pharmacogenomic (PGx), Review results
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 3, 2026, 5:34 AM EDT
Terminated Not applicable Interventional Results available

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

NCT01426516
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 3, 2026, 5:34 AM EDT
Terminated Not applicable Interventional

Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery

NCT03455751
View directory record Official record
Conditions
Colorectal Cancer, Diverticular Disease, Crohn Disease, Ulcerative Colitis
Interventions
PGx-guided post-operative pain management
Genetic
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 3, 2026, 5:34 AM EDT